Clinical Trials Logo

Chronic Fatigue clinical trials

View clinical trials related to Chronic Fatigue.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05367245 Recruiting - Clinical trials for Neurocognitive Dysfunction

Ca-Mg Butyrate in GWI

Butyrate
Start date: January 15, 2024
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restoring gut microbiome and virome, (b) decreasing gastrointestinal disturbances (constipation, diarrhea, pain), (c) decreasing chronic fatigue, (d) decreasing systemic inflammation, and (e) a decrease in cognitive deficits.

NCT ID: NCT02517151 Recruiting - Clinical trials for Inflammatory Bowel Disease

Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue

MICI_2011-01
Start date: October 2014
Phase: Phase 2
Study type: Interventional

A phase 2, randomized, placebo controlled trial evaluating the effects of n intravenous iron supplementation on chronic fatigue in IBD patients with controlled disease.

NCT ID: NCT01926132 Recruiting - Chronic Fatigue Clinical Trials

High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study

Start date: August 2013
Phase: Phase 4
Study type: Interventional

Reactive Oxygen Species (ROS) can cause oxidative damage, resulting in oxidation of lipids, proteins and DNA. In fatigue patients, there are some evidences of oxidative damage to DNA. Ascorbic acid was known to protect mitochondrial injury against oxidative stress by depolarizing the mitochondrial membrane. The copy number of mitochondrial DNA(mtDNA) was suggested mitochondrial gene stability and biogenesis and reflected mitochondrial function. There is no evidence ascorbic acid would decrease the mtDNA damage in fatigue patients. The investigators hypothesized that decreasing in mtDNA copy number in salivary and blood sample may be reversed by high-dose vitamin C intravenous injection in fatigue patients. The investigators will compare the mtDNA copy number and fatigue scale between moderate-severe fatigue patients and control group that had not malignant and chronic illness by a randomized controlled trial.